MedTech News
.................... by Andrew Celentano
Genesis MedTech Receives CE Mark Approval for 8 mm Video Endoscope
SINGAPORE, Aug. 6, 2026 /PRNewswire/ — Genesis MedTech has received CE Mark approval for its latest 8 mm video endoscope, marking an important milestone in minimally invasive imaging. Achieving 3D imaging, 4K resolution and fluorescence capability in an 8 mm endoscope has been one of the key engineering challenges in advanced surgical visualisation.
Sight Sciences wins FDA clearance for Omni Surgical System
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Omni Ultra Surgical System (Omni Ultra) for canaloplasty followed by trabeculotomy for the reduction of intraocular pressure (IOP) in adult patients with primary open-angle glaucoma (POAG).
BlueWind Medical earns FDA clearance for next-gen tibial neuromod system
BlueWind Medical announced today that it received FDA 510(k) clearance for Revi Extend, its next-generation implant.
New biobank of tumor models reveals cancers’ weak spots
A new open resource of cancer models has enabled researchers to create the first large-scale map of the genes that cancers rely on to survive, offering new avenues for research into better and less toxic treatments for patients.
RNA technology improves insulin-producing cell transplantation outcomes
Researchers from the Rolf Luft Research Center for Diabetes and Endocrinology at Karolinska Institutet have developed a targeted RNA technology to prepare pancreatic islet cells for transplantation.
How ‘good’ bacteria from fecal transplants reduce peanut allergy
Some 33 million Americans have severe food allergies. Now, researchers at Boston Children’s Hospital may have found a promising solution.
First-in-class small molecule inhibitor shows promise against pancreatic cancer in preclinical studies
Mayo Clinic researchers have developed an experimental drug with the help of artificial intelligence (AI) to target the “undruggable” PDZ domain of the GIPC1 protein, which helps different types of cancer, including pancreatic cancer, grow and resist treatment. In laboratory studies, the drug slowed tumor growth, improved survival and enhanced the effects of the chemotherapy drug gemcitabine.
A new drug that can potentially overcome cancer therapy resistance
Researchers at Baylor College of Medicine have developed a drug called CS18 that disrupts cancer cells’ ability to survive therapy. The findings, published in Science Advances, support exploring the possibility of using CS18 to treat human cancer in the future.